Expanded study of vancomycin therapy drug monitoring and gene polymorphism in Chinese population

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023287

Enrollment

Unknown

Registered

2019-05-20

Start date

2018-11-01

Completion date

Unknown

Last updated

2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Interventions

AKI Group:No.

None-AKI Group:No.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Patients admitted in each center from November 1, 2018 to December 31, 2019; 2) Patients' age = 18 years old; 3) Vancomycin was prescribed by the physician.

Exclusion criteria

Exclusion criteria: (the marked item by * is only the exclusion criteria for the study of gene polymorphism) 1) Chronic dialysis patients; *2) Patients with chronic renal failure (CKD 4-5 stage); *3) Patients with acute renal injury before vancomycin treatment ; *4) Patients who have not signed the informed consent; 5) Patients who are considered unfit for enrollment by researchers; 6) Patients who are unwilling to participate in the study.

Design outcomes

Primary

Measure	Time frame
Gene Locus;steady plasma-drug concentration;	—

Countries

China

Contacts

Public ContactLi Yang

Peking University First Hospital

li.yang@bjmu.edu.cn+86 010 83572776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026